SCHEMBL675100

SCHEMBL675100

CCCC(N)Cc1ccc2c(n1)[nH]c1ccc(C=Cc3ccccc3)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 3/20 0.37
CA5A P35218 1/20 0.34
ALK Q9UM73 4/20 0.33
MAPKAPK2 P49137 1/20 0.32
GAA P10253 2/20 0.31
IP6K3 Q96PC2 1/20 0.31
IP6K2 Q9UHH9 1/20 0.31
KDM4E B2RXH2 2/20 0.30
RAB9A P51151 2/20 0.30
L3MBTL1 Q9Y468 2/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
RELA Q04206 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
GLA P06280 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675671 0.89 ALK (0.37) ALKKDM4ERAB9AMAPTRELA
SCHEMBL676564 0.85 IP6K1 (0.37) IP6K1CA5AALKMAPKAPK2GAA
SCHEMBL676203 0.84 GSK3B (0.37) CA5AALK
SCHEMBL676277 0.81 IP6K1 (0.37) IP6K1CA5AALKMAPKAPK2IP6K3
SCHEMBL3725585 0.81 GABRP (0.40) IP6K1ALKMAPKAPK2GAAKDM4E
SCHEMBL3725587 0.81 GABRP (0.40) IP6K1ALKMAPKAPK2GAAKDM4E
SCHEMBL675097 0.79 IP6K1 (0.37) IP6K1CA5AALKMAPKAPK2IP6K3
SCHEMBL675790 0.76 GABRA1 (0.39) ALK
SCHEMBL677055 0.76 ALK (0.37) ALKKDM4ERAB9AMAPTRELA
SCHEMBL675098 0.75 IP6K1 (0.36) IP6K1CA5AALKMAPKAPK2IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 IP6K1 3330/4885CA5A 1904/4885ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.